Highlights: CfDNA offers a non-invasive way to detect and monitor diseases like cancer and genetic conditions
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Maroc - ONCOLOGYNEWS.COM.AU - A La Une - 21/Aug 13:52
SwRI develops novel DNA-targeting therapeutic screening technique
Southwest Research Institute (SwRI) in the USA, has developed a unique technology to screen new DNA-targeting therapeutics designed to treat cancer and other diseases. Combining SwRI’s 3D drug screening software tool and machine learning techniques, SwRI scientists successfully predicted the DNA binding affinity and cancer cell toxicity for a variety of relevant drug compounds under [...]
Articles similaires
TC BioPharm to begin Proof of Concept preclinical studies for its lead therapeutic TCB 008 to treat monkey pox
pharmabiz.com - 09/Sep 00:00
TC BioPharm (Holdings) PLC (TC BioPharm), a clinical stage biotechnology company developing platform allogeneic gamma─delta T cell therapies for...
Relay Therapeutics reports positive interim data for RLY─2608 demonstrating clinically meaningful progression free survival
pharmabiz.com - 10/Sep 00:00
Relay Therapeutics, Inc., a clinical─stage precision medicine company transforming the drug discovery process by combining leading─edge...
Aethlon Medical to Present at the Life Sciences Investor Forum September 19th
financialpost.com - 13/Sep 12:38
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com SAN...
Aethlon Medical to Present at the Life Sciences Investor Forum September 19th
financialpost.com - 13/Sep 12:38
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com SAN...
Data Shows Cell-Free DNA Test Predicts Colorectal Cancer Survival
medindia.net - 00:35
A new GALAXY study reveals Signatera's cell-free DNA test predicts survival rates and chemotherapy benefits for colorectal cancer patients with high...
Data Shows Cell-Free DNA Test Predicts Colorectal Cancer Survival
medindia.net - 00:35
A new GALAXY study reveals Signatera's cell-free DNA test predicts survival rates and chemotherapy benefits for colorectal cancer patients with high...
Stealth BioTherapeutics to receive FARA grant to develop investigational mitochondrial therapeutic SBT─589 for Friedreich's ataxia
pharmabiz.com - 13/Sep 16:48
Stealth BioTherapeutics Inc., a clinical─stage biotechnology company focused on the discovery, development and commercialization of novel therapies...
Stealth BioTherapeutics to receive FARA grant to develop investigational mitochondrial therapeutic SBT─589 for Friedreich's ataxia
pharmabiz.com - 13/Sep 16:48
Stealth BioTherapeutics Inc., a clinical─stage biotechnology company focused on the discovery, development and commercialization of novel therapies...
Novel intermediate form of serotonin receptor identified as therapeutic target for psychiatric disorders
news.medical.net - 04/Sep 16:59
Misha Kudryshev's lab at the Max Delbrück Center has identified a molecular intermediate of a serotonin receptor that is involved in diseases such as...
Les derniers communiqués
-
Aucun élément